Homepage > Company > Media > Pharma News > 2022 > Pfizer to Supply Up to Six Million Paxlovid Treatment Courses to Global Fund

Pfizer to Supply Up to Six Million Paxlovid Treatment Courses to Global Fund

Pfizer has promised to supply up to six million treatment courses of its Paxlovid (nirmatrelvir, ritonavir) to the Global Fund for treatment of COVID-19 infections.

The oral drugs will be made available to low- and middle-income countries at a not-for-profit price while upper-middle-income countries will pay tiered pricing, the company said.

Paxlovid is currently FDA-authorized for treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg.

Contractual details of the Global Fund agreement were not disclosed.

September 23, 2022

https://www.fdanews.com/

Read also

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Pfizer’s antibiotic combination, Emblaveo (aztreonam-avibactam), has been approved by the European Commission (EC) to treat patients with multidrug-resistant infections.

FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for BCG-Unresponsive NMIBC

The FDA has approved nogapendekin alfa inbakicept-pmln (Anktiva; N-803) in combination with Bacillus Calmette–Guérin (BCG) for the treatment of adult patients with BCG-unresponsive ...

Investigational Cushing’s syndrome medication reduces BP, glucose in open-label trial

Adults with endogenous Cushing’s syndrome had reductions in blood pressure and glucose at 22 weeks of treatment with a selective cortisol modulator, according to topline results from the open-label ...

Ipsen and Skyhawk announce $1.8bn partnership to advance rare neurological disease therapies

Ipsen and Skyhawk Therapeutics have announced an exclusive worldwide collaboration aimed at advancing RNA-targeting therapies for rare neurological diseases, with the deal worth more than $1.8bn.